Tag:
Biogen Idec
Latest Headlines
Latest Headlines
TheStreet: A roundup of the top drug studies left in 2012
Any forward-looking student of the biotech industry will have to check out Adam Feuerstein's review in TheStreet of 22 Phase II and III clinical trials--21 drugs and one diagnostic test--which are expected to read out by the end of this year.
Investors pocket $761M in deal betting on Biogen's BG-12
Like a lot of biotech investors, Royalty Pharma sees blockbuster potential in Biogen Idec's ($BIIB) experimental BG-12.
Biogen Idec builds blockbuster case for new MS drug BG-12
Biogen Idec is backing up its blockbuster expectations for the MS drug BG-12 with a slate of efficacy and safety data gathered in a late-stage study.
Samsung says its manufacturing 'DNA' will provide big biosimilar savings
Mention South Korea's prowess in manufacturing and you might think of cheap cars or inexpensive electronics. How about biosimilars?
Samsung plans ambitious rollout of biosims at deep discounts
Samsung BioLogics is moving fast with some ambitious plans to start marketing biosmilars at a deep discount while striking more development deals.
RNAi developer Arrowhead snags startup Alvos in stock deal
Arrowhead Research has bought Alvos Therapeutics and the small company's peptides that home in on tumor targets.
Icahn goes in for the kill at Amylin
In an open letter, the feared raider lambasted the company for handing out stock options at $16 a share when it was keeping quiet about Bristol-Myers Squibb's $22 a share bid.
Biogen Idec bets it can succeed on a risky Phase III ALS gamble
Bloomberg biotech scribe Meg Tirrell has been plumbing Biogen Idec's late-stage drug for ALS and finds some good reasons to believe that they are on to something big.
Biogen chief brings in $11.3M in 2011 pay
Biogen Idec ( $BIIB ) CEO George Scangos (pictured) has restructured the company, streamlined R&D and benefited from drug development begun before his term began.
Biogen executive team rakes in millions from its 2011 successes
With the company's share price trading at an all-time high, it's not going to surprise many to see execs pulling down big money.
